Table 1.
Antecollis induced by pramipexole in patients with Parkinson's disease.
| Authors | Age (year)/sex | HY stage | Duration (year) | PPX dosed (mg/d) | Interval from starting PPX to appearance of antecollis | Treatment | Combined drugs/d |
|---|---|---|---|---|---|---|---|
| Suzuki et al. 8) | 80/F | 4 | 3 | 3 | Few weeks | Cessation of PPX | l-dopa/carbidopa 200 mg |
| Oyama et al. 9) | 75/F | 3 | 6 | UD | 8 weeks | Reduction | UD |
| 64/F | 3 | 9 | UD | 4 weeks | Reduction of PPX | UD | |
| 79/F | 3 | 17 | UD | 4 weeks | Cessation of PPX | UD | |
| Taguchi et al. 10) | 80/F | UD | 3 | 1 | 1.5 years | Cessation of PPX Increase dose of l-dopa |
none |
| Uzawa et al. 11) | 64/F | 4 | 6 | 2.5 | Few weeks | Cessation of PPX | l-dopa/benserazid 450 mg |
| 47/F | 4 | 5 | 1 | 2 weeks | Cessation of PPX |
l-dopa/carbidopa 50 mg, Cabergoline 3 mg |
|
| Kashihara et al. 6) | UD | UD | UD | UD | Few weeks | Cessation of PPX | UD |
| UD | UD | UD | UD | Few weeks | Cessation of PPX | UD | |
| Kim et al. 13) | 80/F | UD | 3 | 1 | 6 weeks | Cessation of PPX | l-dopa/benserazid 450 mg |
| Our patient 1 | 64/F | 3 | 7 | 3 | 4 years | Reduction of PPX 1.5 mg, and Overnight switched from PPX to ROP 6 mg |
l-dopa/carbidopa 300 mg, Entacapone 300 mg, Zonisamide 2.5 mg |
| patient 2 | 71/F | 2 | 4 | 1.5 | 3 years | Overnight switched from PPX to ROP 6 mg | l-dopa/carbidopa 300 mg, |
HY stage; Hoehn and Yahr stage, UD; undescribed, PPX; pramipexole, ROP; ropinirole.